Moderna 8-K

Summary

Moderna completed a $3.0B private placement of 0.00% convertible senior notes due 2032, including full exercise of the purchasers’ $400M option. The notes are senior unsecured obligations; capped calls are intended to reduce conversion dilution or offset certain cash payments, subject to a cap.

Key Figures

• Principal: $3.0B; maturity 3/1/2032. The notes bear no regular interest and do not accrete.
• Net proceeds: $2.96B after discounts, commissions and estimated expenses; $328.8M paid for capped calls. Remaining proceeds are for general corporate purposes, potentially including oncology investment and debt repayment.
• Initial conversion rate: 4.7487 shares per $1,000 principal, equivalent to a $210.58 conversion price and a 47.5% premium to the 8/27/2026 share price of $142.77. The notes are convertible into 14,246,100 shares initially, or up to 21,012,600 in limited circumstances.
• Capped calls cover the shares initially underlying the notes, with an initial cap price of $393 per share, 175% above the 8/27/2026 share price.

Investor Takeaways

• Watch how Moderna allocates the remaining proceeds, including any oncology investment or debt repayment.